Orasi Medical has opened its new Tokyo office. The new office is expected to allow Orasi Medical to aid Japanese pharmaceutical companies in developing medicines for CNS diseases such as alzheimer’s disease, multiple sclerosis, schizophrenia, parkinson’s disease, and migraine.
According to Orasi Medical its new office in Tokyo is expected to focus on the clinical service to pharmaceutical companies in the Asia Pacific and the EU. Powered by its Synchronous Neural Interaction Test (SNI Test), patients are likely to receive an objective assessment of brain function with a quick, 10-minute MEG scan.
Joseph Baxter, representative director for Asia Pacific and EU for Orasi Medical, said: “With the fastest growing aging population in the world, the Japanese market is a growing focal point for many of the pharmaceutical and medical companies who are determined to reach this population and solve this economic and medical crisis. We look forward to solving this problem by providing the only non-invasive test that tracks Alzheimer’s disease progression from early stage to late stage which may lead to better treatments for Alzheimer’s.”
Shawn Lyndon, chairman and CEO of Orasi Medical, said: “Our expansion into the fast growing Japanese market presents significant future revenue growth opportunities for the company and greatly expands our footprint in the Asia-Pacific region.”
The new Tokyo office will be located at the JETRO Invest Japan Business Support Center